Implementing precision medicine in a regionally organized healthcare system in Sweden. Correspondence from rosenquistbrand genomicmedswe and colleagues
We would like to thank T. Åkerblom for her assistance with the preparation of the manuscript. We thank the patient associations Rare Diseases Sweden and the Network Against Cancer for our close collaboration, as well as the GMS Steering Board and SciLifeLab for their continuous support.
School of Engineering Sciences in Chemistry, Biotechnology and Health, Clinical Genomics Stockholm, Science Life Laboratory, KTH Royal Institute of Technology, Stockholm, SwedenDepartment of Immunology, Genetics and Pathology, Clinical Genomics Uppsala, Science for Life Laboratory, Uppsala University, Uppsala, SwedenDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm,...
Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research, Karolinska Institutet, Solna, SwedenDepartment of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, SwedenTherese FagerqvistKina Höglund, Lovisa Lovmar, Ann Nordgren & Per Sikora
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Advancing T cell–based cancer therapy with single-cell technologies - Nature MedicineTo accelerate the development of T cell–based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day’s workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed — with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.
Consulte Mais informação »
Balancing speed, science and regulatory requirements in oncology drug development - Nature MedicineBalancing speed, science and regulatory requirements in oncology drug development. Correspondence from Alexandra Snyder generate_biomed, PritiHegde Foundation Medicine, and colleagues
Consulte Mais informação »
Mother Nature over medicine cabinets: Utahns seek natural remedies to feel betterMore Utahns are using different forms of alternative medicine to better manage physical and mental illness.
Consulte Mais informação »
The Power of Nature to Improve Public Health - The New Yorker FestivalJoin the NewYorker on Friday, October 7th at 6 PM for their virtual event, The Power of Nature to Improve Public Health. A panel of experts will be discussing why planetary health is human health. For more information:
Consulte Mais informação »
CLN3 is required for the clearance of glycerophosphodiesters from lysosomes - NatureThe lysosomal transmembrane protein CLN3 is required for the lysosomal clearance of glycerophosphodiesters in mice and in human cells, suggesting that the loss of CLN3 causes Batten disease in children due to defects in glycerophospholipid metabolism.
Consulte Mais informação »